EUVIMEDEUVIMED entdecken
Crossref

The genotyping of UGT1A1 polymorphism for the dose adjustment of irinotecan in metastatic colorectal cancer patients treated with FOLFIRI plus bevacizumab as the first-line regimen

Chien-Yu Lu, Hsiang-Lin Tsai, Jaw-Yuan Wang

Biomarkers and Genomic Medicine · 2013

DOI: 10.1016/j.bgm.2013.08.020 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomarkers and Genomic Medicine, 2013. Verfasst von Chien-Yu Lu und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Lu, C., Tsai, H., & Wang, J. (2013). The genotyping of UGT1A1 polymorphism for the dose adjustment of irinotecan in metastatic colorectal cancer patients treated with FOLFIRI plus bevacizumab as the first-line regimen. Biomarkers and Genomic Medicine. https://doi.org/10.1016/j.bgm.2013.08.020

Vancouver

Lu C, Tsai H, Wang J. The genotyping of UGT1A1 polymorphism for the dose adjustment of irinotecan in metastatic colorectal cancer patients treated with FOLFIRI plus bevacizumab as the first-line regimen. Biomarkers and Genomic Medicine. 2013. doi:10.1016/j.bgm.2013.08.020

BibTeX
@article{Lu2013,
  author = {Lu, Chien-Yu and Tsai, Hsiang-Lin and Wang, Jaw-Yuan},
  title = {The genotyping of UGT1A1 polymorphism for the dose adjustment of irinotecan in metastatic colorectal cancer patients treated with FOLFIRI plus bevacizumab as the first-line regimen},
  journal = {Biomarkers and Genomic Medicine},
  year = {2013},
  doi = {10.1016/j.bgm.2013.08.020}
}
Kostenlos starten →